Author: Olivier Fakih
Michel et al. (2222) compared patients with a SpA + IBD codiagnosis versus those with only one diagnosis in a retrospective monocentric study. 62 patients with a codiagnosis were compared with 100 SpA and 100 patients. In both cases, SpA+IBD patients were older at diagnosis, had more uveitis, psoriasis, smoking, and used more bDMARDs for the same duration. Patients with a codiagnosis had a higher endoscopic severity score (HBI) at diagnosis versus IBD-only patients (8.2(±5.7) vs 2.6(±3.1) p<0.001).
Torgutalp et al. (2220) determined the factors associated with achieving remission in patients with early pSpA using 10-year data from the GRESPIC cohort (predominant peripheral manifestations, symptom duration up to 5 years and not classified as axSpA). 115 pSpA patients were included, 71 (61.7%) patients were HLA-B27 positive. Multivariable analyses showed that history of psoriasis, HLA-B27 negativity, steroid intake, and higher NSAID intake were associated with higher DAPSA and ASDAS scores. In contrast, longer symptom duration, psoriasis history, steroid, TNFi, higher NSAID intake, and higher CRP were associated with lower odds of remission.
Molto et al. (0842) studied the rate of switching from non-radiographic to radiographic axSpA. 299 patients completed the 10-year follow-up period, and 704 participants were included in an intention-to-follow analysis. In the completers, the net % of progressors was 5.7%. Sacro-iliac bone marrow oedema on MRI, male sex, symptom duration >1.5 years, ASDAS >2.1 and smoking were associated with progression.
Karmacharya et al. (1642) identified distinct phenotypes in PsA using cluster analysis in the multicentric PARC cohort. Five clusters were separated with different features regarding disease activity, joint counts, PROs and psoriasis.
De Bruin et al. (0843) analysed the predictive validity of the proposed cut-offs for active and structural MRI-SIJ lesions in early axSpA by the ASAS MRI group after two years of follow-up. All but one of the definitions were validated in early axSpA. For erosions, ≥4 consecutive slices instead of ≥2 was suggested.
Marques et al. (0845) assessed the yield of repeated assessments of SpA features over 2 years to make a definite axSpA diagnosis in patients with recent onset chronic back pain. The diagnosis changed to definite axSpA in 32 out of 337 patients. Sacroiliitis on MRI and response to NSAIDs were the two most frequently incident SpA features potentially adding to a definite diagnosis over time.
Daoud et al. (1399) analysed CV mortality in patients with AS in the era of b/tsDMARDs using US Death Certificate Data. The age-adjusted mortality rate was 0,7/1000000 with 22% due to CV causes. The proportionate CV mortality decreased from 34% in 1999 to 21% in 2020 (trend P< 0.001).
ABOUT THE AUTHOR
Olivier Fakih
Olivier is a rheumatology clinical instructor at the Department of Rheumatology of Besançon University Hospital in France.
His research interests include the epidemiology of inflammatory rheumatic diseases, in particular mortality and comorbidities in spondyloarthritis. Olivier is a member of the French Society of Rheumatology and the society’s young rheumatologists section.
He is a member of the EMEUNET Social Media sub-committee, in the podcast team.